News & Updates

Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.

Oteseconazole (VT-1161), a novel investigational fungal CYP51 inhibitor, outdid fluconazole/placebo for managing acute and recurrent* vulvovaginal candidiasis (VVC), according to data from the phase III ultraVIOLET trial.

Undiagnosed depression, depressive symptoms, and suicidal ideation are all common among Hong Kong doctors, a recent study has found.

Hepatocellular carcinoma (HCC) in Singapore has changed markedly throughout the last decade, with patients being diagnosed at an increasingly older age and cryptogenic cirrhosis/nonalcoholic steatohepatitis (NASH) becoming a more important aetiology, according to a recent study.

Treatment with leuprolide acetate every 6 months does not elicit significant changes in health-related quality of life (HRQOL) among prostate cancer (PC) patients despite substantial deterioration of body and role functions, a recent study has found.

Intravenous dosing regimens of vedolizumab appear to favourably alter outcomes in patients with fistulizing Crohn’s disease, according to data from the phase IV ENTERPRISE trial.

Collagen proportionate area (CPA) is a good predictor of long-term mortality in alcoholic hepatitis (AH) patients regardless of their abstinence from alcohol, a recent study has found. However, CPA seems to have no clear interaction with short-term mortality.

A large international database study has shown that children and adolescents with cancer have an elevated risk of severe or critical disease if infected with COVID-19. Furthermore, about half the patients receiving cancer therapy experienced modifications to their treatment regimens.